Wooree Bio Co.,Ltd (KOSDAQ:082850)
2,330.00
-45.00 (-1.89%)
At close: Mar 27, 2025, 3:30 PM KST
Wooree Bio Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 1,237,198 | 1,263,944 | 1,355,056 | 1,543,312 | 1,623,383 | Upgrade
|
Other Revenue | - | -0 | - | - | 0 | Upgrade
|
Revenue | 1,237,198 | 1,263,944 | 1,355,056 | 1,543,312 | 1,623,383 | Upgrade
|
Revenue Growth (YoY) | -2.12% | -6.72% | -12.20% | -4.93% | -2.94% | Upgrade
|
Cost of Revenue | 1,119,187 | 1,148,606 | 1,241,417 | 1,427,899 | 1,523,846 | Upgrade
|
Gross Profit | 118,012 | 115,337 | 113,639 | 115,412 | 99,537 | Upgrade
|
Selling, General & Admin | 84,804 | 74,363 | 65,396 | 57,472 | 47,617 | Upgrade
|
Research & Development | 11,439 | 8,398 | 7,019 | 7,382 | 6,631 | Upgrade
|
Other Operating Expenses | 1,548 | 1,350 | 1,884 | 1,274 | 1,376 | Upgrade
|
Operating Expenses | 102,812 | 89,355 | 79,398 | 72,995 | 62,095 | Upgrade
|
Operating Income | 15,200 | 25,982 | 34,241 | 42,417 | 37,442 | Upgrade
|
Interest Expense | -5,402 | -6,052 | -4,948 | -4,438 | -6,468 | Upgrade
|
Interest & Investment Income | 4,365 | 3,834 | 1,632 | 427.15 | 320.28 | Upgrade
|
Earnings From Equity Investments | -79.77 | -190.83 | -123.76 | -184.23 | 13.08 | Upgrade
|
Currency Exchange Gain (Loss) | 8,637 | -1,908 | -116.95 | 4,510 | -2,077 | Upgrade
|
Other Non Operating Income (Expenses) | 3,829 | 250.77 | 1,224 | 2,566 | 3,930 | Upgrade
|
EBT Excluding Unusual Items | 26,548 | 21,917 | 31,909 | 45,298 | 33,161 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | 188.71 | -1,865 | Upgrade
|
Gain (Loss) on Sale of Assets | 317.61 | -187.34 | 117.01 | -206.37 | -9,019 | Upgrade
|
Asset Writedown | -2,327 | - | - | - | -52.45 | Upgrade
|
Pretax Income | 24,539 | 21,729 | 32,026 | 45,281 | 22,224 | Upgrade
|
Income Tax Expense | 16,312 | 2,783 | 6,900 | 1,239 | 5,241 | Upgrade
|
Earnings From Continuing Operations | 8,227 | 18,946 | 25,126 | 44,041 | 16,983 | Upgrade
|
Net Income to Company | 8,227 | 18,946 | 25,126 | 44,041 | 16,983 | Upgrade
|
Minority Interest in Earnings | -3,483 | -3,365 | -3,304 | -10,886 | -141.65 | Upgrade
|
Net Income | 4,743 | 15,581 | 21,822 | 33,156 | 16,841 | Upgrade
|
Net Income to Common | 4,743 | 15,581 | 21,822 | 33,156 | 16,841 | Upgrade
|
Net Income Growth | -69.56% | -28.60% | -34.18% | 96.87% | 271.64% | Upgrade
|
Shares Outstanding (Basic) | 47 | 47 | 46 | 44 | 44 | Upgrade
|
Shares Outstanding (Diluted) | 47 | 47 | 46 | 48 | 45 | Upgrade
|
Shares Change (YoY) | 0.15% | 1.86% | -2.87% | 5.70% | - | Upgrade
|
EPS (Basic) | 100.00 | 331.00 | 469.36 | 750.13 | 385.66 | Upgrade
|
EPS (Diluted) | 100.00 | 329.00 | 469.00 | 702.06 | 376.03 | Upgrade
|
EPS Growth | -69.60% | -29.85% | -33.20% | 86.70% | 253.57% | Upgrade
|
Free Cash Flow | -45,711 | 16,018 | 30,085 | 38,588 | 52,167 | Upgrade
|
Free Cash Flow Per Share | -963.73 | 338.22 | 647.10 | 806.13 | 1151.92 | Upgrade
|
Gross Margin | 9.54% | 9.13% | 8.39% | 7.48% | 6.13% | Upgrade
|
Operating Margin | 1.23% | 2.06% | 2.53% | 2.75% | 2.31% | Upgrade
|
Profit Margin | 0.38% | 1.23% | 1.61% | 2.15% | 1.04% | Upgrade
|
Free Cash Flow Margin | -3.69% | 1.27% | 2.22% | 2.50% | 3.21% | Upgrade
|
EBITDA | 42,731 | 57,832 | 70,435 | 77,974 | 76,287 | Upgrade
|
EBITDA Margin | 3.45% | 4.58% | 5.20% | 5.05% | 4.70% | Upgrade
|
D&A For EBITDA | 27,531 | 31,850 | 36,194 | 35,557 | 38,845 | Upgrade
|
EBIT | 15,200 | 25,982 | 34,241 | 42,417 | 37,442 | Upgrade
|
EBIT Margin | 1.23% | 2.06% | 2.53% | 2.75% | 2.31% | Upgrade
|
Effective Tax Rate | 66.47% | 12.81% | 21.54% | 2.74% | 23.58% | Upgrade
|
Advertising Expenses | 8,170 | 9,177 | 8,633 | 3,642 | 246.06 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.